SEC 13F Intelligence

Venrock Adviser, LLC / DNTH

Venrock Adviser, LLC’s Dianthus Therapeutics Inc Position

Does Venrock Adviser, LLC own Dianthus Therapeutics Inc (DNTH)? Yes — 1.18M shares worth $99M (+3.70% of its 13F portfolio) as of Q1 2026, up from 1.00M shares the prior filed quarter.

Position Value
$99M
Q1 2026
Shares
1.18M
% of Portfolio
+3.70%
Quarters Held
11
currently held

Position History DNTH

Reported value by quarter
Q3 ’23: $13MQ3 ’23Q4 ’23: $10MQ1 ’24: $63MQ1 ’24Q2 ’24: $54MQ3 ’24: $48MQ3 ’24Q4 ’24: $38MQ1 ’25: $32MQ1 ’25Q2 ’25: $19MQ3 ’25: $38MQ3 ’25Q4 ’25: $41MQ1 ’26: $99MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.18M$99M+3.70%
Q4 20251.00M$41M+2.04%
Q3 2025960.8K$38M+2.13%
Q2 20251.00M$19M+1.40%
Q1 20251.74M$32M+2.69%
Q4 20241.74M$38M+2.61%
Q3 20241.74M$48M+2.50%
Q2 20242.09M$54M+3.45%
Q1 20242.09M$63M+2.99%
Q4 2023927.7K$10M+0.66%
Q3 2023927.7K$13M+1.33%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Venrock Adviser, LLC’s full portfolio or all institutional holders of DNTH.